secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2026-04-15T23:59:59+00:00
Accession:  0001104659-26-043781
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma FY2025 net income $9.2M (vs loss $166.5M); $60M PIPE with $10M upfront funds into Q1 2027
--------------------------------------------------------------------------------

- FY2025 net income $9.2M ($0.83 basic EPS) vs net loss $166.5M ($35.21 loss/share) in FY2024; revenue $2.8M (up from $0.2M).
- Cash and equivalents $3.8M at Dec 31, 2025; PIPE up to $60M with $10M upfront to fund operations into Q1 2027.
- TXM (influenza) Phase 1 bridging study ongoing; expects MHRA approval for human challenge trial in Q2 2026; FDA clinical hold unresolved.
- Ratutrelvir (COVID) Phase 2a topline: faster symptom resolution in PAXLOVID-ineligible patients (HR 1.31, p=0.018); fewer adverse events vs comparator.
- CEO Iain Dukes and CFO Charles Parker confirmed Oct 2025; John Leaman appointed independent director.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465926043781/0001104659-26-043781-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465926043781/tm2611843d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-043781

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer